PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes 10 Sept Written By Alexandra Collingbourne Alexandra Collingbourne
PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes 10 Sept Written By Alexandra Collingbourne Alexandra Collingbourne
